Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components

NCT04895059 | Completed Phase 1

• 1 other identifier: RSEZ-25-SIL
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe 10 mg. An open design, randomized, single dose with three periods, six sequences and crossed, in healthy volunteers with fasting conditions, managed in fixed dose combination (Sponsor Laboratorios Silanes S.A. de C.V.) versus individual components managed by separated (Crestor®, product of Astrazeneca, S.A. de C.V and Ezetrol®. product of Undra S.A. de C.V.)

Conditions

Healthy

Keywords

Dyslipidemia; Rosuvastatin; Ezetimibe; Cholesterol

Outcome Measures

Primary Outcomes (4)

• Maximum observed concentration following the treatment (Cmax

  Evaluate the fixed dose pharmacokinetics profile of rosuvastatin/ezetimibe, employing the maximum observed concentration following the treatment (Cmax)

  Baseline, 0.25, 0.50, 0.75, 1.00. 2.00, 3.00, 4.00, 5.00, 6.00. 7.00, 8.00, 10.00, 14.00, 24.00. 36.00, 48.00. 72.00 and 96.00 hours

• The area under the curve from time zero to the last measurable concentration (AUC 0-t)using the linear trapezoidal linear-interpolation method

  Evaluate the fixed dose pharmacokinetics profile of rosuvastatin/ezetimibe, employing the area under the curve from time zero to the last measurable concentration (AUC 0-t)using the linear trapezoidal linear-interpolation method.

  Baseline, 0.25, 0.50, 0.75, 1.00. 2.00, 3.00, 4.00, 5.00, 6.00. 7.00, 8.00, 10.00, 14.00, 24.00. 36.00, 48.00. 72.00 and 96.00 hours

• The area under the curve from time zero to infinity calculated (AUC 0-inf),

  Evaluate the fixed dose pharmacokinetics profile of rosuvastatin/ezetimibe, employing the area under the curve from time zero to infinity calculated (AUC 0-inf).

  Baseline, 0.25, 0.50, 0.75, 1.00. 2.00, 3.00, 4.00, 5.00, 6.00. 7.00, 8.00, 10.00, 14.00, 24.00. 36.00, 48.00. 72.00 and 96.00 hours

• Time of the maximum measured concentration (Tmax).

  Evaluate the fixed dose pharmacokinetics profile of Rosuvastatin/ezetimibe, employing time of the maximum measured concentration (Tmax).

  Baseline, 0.25, 0.50, 0.75, 1.00. 2.00, 3.00, 4.00, 5.00, 6.00. 7.00, 8.00, 10.00, 14.00, 24.00. 36.00, 48.00. 72.00 and 96.00 hours

Secondary Outcomes (5)

• Sitting blood pressure (mmHg).

  Prior to dosing, at 02.00, 06.00,14.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours

• Pulse rate (p/m).

  Prior to dosing, at 02.00, 06.00,14.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours

• Respiratory rate (rr).

  Prior to dosing, at 02.00, 06.00,14.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours

• Axillary-body temperature (°C).

  Prior to dosing, at 02.00, 06.00,14.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours

• Adverse events

  96 hours

Study Arms (3)

Group A: Rosuvastatin / Ezetimibe fixed dose

EXPERIMENTAL

In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral

Drug: Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose

Group B: Rosuvastatin (Crestor®)

ACTIVE COMPARATOR

Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral

Drug: Rosuvastatin 20mg

Group C: Ezetimibe (Ezetrol®)

ACTIVE COMPARATOR

Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral

Drug: Ezetimibe 10mg

Interventions

Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose DRUG

Form: Tablets Dosage: 20 mg Adminstration way: Oral

Also known as: ROSU/EZET

Group A: Rosuvastatin / Ezetimibe fixed dose

Rosuvastatin 20mg DRUG

Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral

Also known as: ROSU (Crestor®)

Group B: Rosuvastatin (Crestor®)

Ezetimibe 10mg DRUG

Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral

Also known as: EZET (Ezetrol®)

Group C: Ezetimibe (Ezetrol®)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• The body mass index of the subjects should be between 18.0-27.0 according to Quetelet.
• Women of childbearing age should have a family planning method (including barrier methods, non-hormonal intrauterine devices or bilateral tubal obstruction) or practice abstinence as a lifestyle during the development of the clinical study.
• Volunteers must be healthy, a criterion determined by the results of a complete medical history carried out by the doctors of the Clinical Research site and the laboratory and cabinet studies carried out in certified Clinical Laboratories.
• The limits of variation allowed within normality in the selection visit will be: blood pressure (sitting) from 90 to 130 mmHg systolic and 60 to 90 mmHg diastolic, heart rate between 50 and 100 beats per minute and respiratory rate between 14 and 20 breaths per minute according to current SOP with code CLI-DES-008 " Measure vital sign".
• The vital signs will be taken after 5 minutes of rest in the sedent position.

You may not qualify if:

• Volunteers with a history of cardiovascular, neurological (uncontrolled seizures), kidney (severe kidney failure), liver (liver failure, active liver disease or increased transaminases that exceed three times the upper limit of normal), pulmonary, muscular (myopathies) ), rhabdomyolysis, hereditary muscle disorders), metabolic, gastrointestinal including constipation, neurological, endpocrine (diabetes mellitus, hypothyroidism), hematopoietic or any type of anemia, mental illness or other organic abnormalities. As well as those who have had a muscle trauma within the 21 days prior to the study.
• Volunteers who require any medication during the course of the study other than the medication being studied.
• Volunteers with a history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer.
• History of hereditary galactose intolerance, Lapp lactase deficiency, or glucose or galactose malabsorption.
• Volunteers who have been exposed to medications known as liver enzyme inducers or inhibitors or who have taken potentially toxic medications within 30 days prior to the start of the study.
• Volunteers who have received any medications, including vitamins (with or without a prescription) or herbal remedies 30 days (or 7 half-lives) prior to the start of the study.
• Current or recent use of fibrates, niacin, cyclosporine, and protease inhibitors.
• History of muscle toxicity with another HMG-CoA inhibitor or fibrates.
• Volunteers who have been hospitalized for any problem during the six months prior to the start of the study.
• Subjects allergic to any medicine, food or substance. Subjects who have ingested alcohol and / or carbonated and / or xanthine-containing beverages (coffee, tea, cocoa, chocolate, mate, cola soft drinks) or who have ingested charcoal-grilled food or grapefruit juice within 10 hours prior to the start of the hospitalization period, or subjects who smoked tobacco within 10 hours prior to the start of the study.
• Subjects who have donated or lost 450 ml or more of blood within the 60 days prior to the start of the study.
• Subjects with a history of abuse and dependence on alcohol or psychoactive substances.
• Volunteers requiring a special diet for any reason, for example vegetarian.
• Incapacity of any kind that makes it impossible for the volunteer to understand the nature, objective and possible consequences of the study.
• Evidence of uncooperative attitude during the study.

Sponsors & Collaborators

• Laboratorios Silanes S.A. de C.V.: lead

Study Sites (1)

Laboratorio Silanes, S.A. de C.V.

Mexico City, 11000, Mexico

Location

Related Publications (11)

• Chu NN, Chen WL, Xu HR, Li XN. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. Clin Drug Investig. 2012 Dec;32(12):791-8. doi: 10.1007/s40261-012-0013-5.

  PMID: 23109219 BACKGROUND

• Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.

  PMID: 19332456 BACKGROUND

• Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.

  PMID: 19329822 BACKGROUND

• Kanazawa I, Yamaguchi T, Yamauchi M, Sugimoto T. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Intern Med. 2009;48(21):1869-73. doi: 10.2169/internalmedicine.48.2645. Epub 2009 Nov 2.

  PMID: 19881236 BACKGROUND

• Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, Nam CW, Rhee MY, Park TH, Hong TJ, Park S, Ahn Y, Lee N, Jeon HK, Jeon DW, Han KR, Moon KW, Chae IH, Kim HS. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016 Oct;34(5):371-82. doi: 10.1111/1755-5922.12213.

  PMID: 27506635 BACKGROUND

• Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, Janosi A, van Veldhuisen DJ, Barrios V, Fonseca C, McMurray JJ; CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail. 2010 Jan;12(1):66-74. doi: 10.1093/eurjhf/hfp172.

  PMID: 20023047 BACKGROUND

• McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm. 2005 May 15;62(10):1033-47. doi: 10.1093/ajhp/62.10.1033.

  PMID: 15901588 BACKGROUND

• Nakano T, Inoue I, Takenaka Y, Ono H, Katayama S, Awata T, Murakoshi T. Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine. PLoS One. 2016 Mar 29;11(3):e0152207. doi: 10.1371/journal.pone.0152207. eCollection 2016.

  PMID: 27023132 BACKGROUND

• Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011 Jul;13(7):615-28. doi: 10.1111/j.1463-1326.2011.01383.x.

  PMID: 21332628 BACKGROUND

• Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009 Nov;73(11):2110-7. doi: 10.1253/circj.cj-09-0358. Epub 2009 Oct 5.

  PMID: 19801853 BACKGROUND

• Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Res Notes. 2012 May 23;5:251. doi: 10.1186/1756-0500-5-251.

  PMID: 22621316 BACKGROUND

Related Links

• Drungbank. Ezetimibe
• NORMA oficial Mexicana NOM-177-SSA1-2013, Que establece las pruebas y procedimientos para para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los Terceros Autorizados que realicen las pruebas de intercambiabilidad
• NORMA Oficial Mexicana NOM-220-SSA1-2016, Instalación y operación de la farmacovigilancia.

MeSH Terms

Conditions

Dyslipidemias

Interventions

Rosuvastatin Calcium; Ezetimibe

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Sulfonamides; Amides; Organic Chemicals; Fluorobenzenes; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hydrocarbons; Sulfones; Sulfur Compounds; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Azetidines; Azetines

Study Officials

• Araceli G Medina Nolasco, M.D

  Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 17, 2021
• First Posted: May 20, 2021
• Study Start: April 30, 2017
• Primary Completion: January 15, 2018
• Study Completion: January 22, 2018
• Last Updated: August 24, 2021

Record last verified: 2021-08

Data Sharing

• IPD Sharing: Will not share

Locations

ME (1)